Literature DB >> 20736860

The incontinence-associated dermatitis and its severity instrument: development and validation.

Kathleen Borchert1, Donna Z Bliss, Kay Savik, David M Radosevich.   

Abstract

PURPOSE: To develop and test the validity and interrater reliability of the Incontinence-Associated Dermatitis and its Severity Instrument, a novel tool describing incontinence-associated dermatitis and its severity.
METHODS: Investigators consulted 2 certified WOC nurse experts to determine face validity of the instrument. Seven additional certified WOC nurses evaluated the tool for content validity. The instrument was tested for interrater reliability by attendees at the 2007 WOCN Society National Conference and employees at a health care system in Minnesota. Criterion validity was determined by comparing IAD severity scores of testers with those of the 2 WOC experts and PI.
RESULTS: Consultants determined that the instrument had face and content validity. Two hundred forty-seven attendees at the WOCN Society's National Conference (mean nursing experience 25±9 years [mean±SD]), 100 nursing staff in Minnesota: 84 staff nurses (mean nursing experience 17±12 years), and 16 nursing assistants (mean nursing experience 7±7 years) determined that the instrument has content validity. There were no significant differences in scores of IAD severity for the 4 cases among the 3 types of testers (P>.05). Overall agreement between the 347 raters and the experts using intraclass correlation was 0.98 (P=.006).
CONCLUSION: The Incontinence-Associated Dermatitis and its Severity Instrument demonstrated good validity and interrater reliability and its development fulfills an unmet need in both research and clinical practice settings.

Entities:  

Mesh:

Year:  2010        PMID: 20736860     DOI: 10.1097/WON.0b013e3181edac3e

Source DB:  PubMed          Journal:  J Wound Ostomy Continence Nurs        ISSN: 1071-5754            Impact factor:   1.741


  7 in total

1.  The Ghent Global IAD Monitoring Tool (GLOBIAD-M) to monitor the healing of incontinence-associated dermatitis (IAD): Design and reliability study.

Authors:  Karen Van den Bussche; Sofie Verhaeghe; Ann Van Hecke; Dimitri Beeckman
Journal:  Int Wound J       Date:  2018-05-24       Impact factor: 3.315

Review 2.  Incontinence-Associated Dermatitis: Pathogenesis, Contributing Factors, Prevention and Management Options.

Authors:  Hilde Beele; Steven Smet; Nele Van Damme; Dimitri Beeckman
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

3.  Prospective study on Incontinence-Associated Dermatitis and its Severity instrument for verifying its ability to predict the development of pressure ulcers in patients with fecal incontinence.

Authors:  Kyung Hee Park; Heejung Choi
Journal:  Int Wound J       Date:  2016-03       Impact factor: 3.315

Review 4.  Recommendations for managing cutaneous disorders associated with advancing age.

Authors:  Philippe Humbert; Brigitte Dréno; Jean Krutmann; Thomas Anton Luger; Raoul Triller; Sylvie Meaume; Sophie Seité
Journal:  Clin Interv Aging       Date:  2016-02-12       Impact factor: 4.458

5.  Clinical Evaluation of a Skin Protectant for the Management of Incontinence-Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study.

Authors:  Mary R Brennan; Catherine T Milne; Marie Agrell-Kann; Bruce P Ekholm
Journal:  J Wound Ostomy Continence Nurs       Date:  2017 Mar/Apr       Impact factor: 1.741

Review 6.  Management of Moisture-Associated Skin Damage: A Scoping Review.

Authors:  Kevin Y Woo; Dimitri Beeckman; Debashish Chakravarthy
Journal:  Adv Skin Wound Care       Date:  2017-11       Impact factor: 2.347

7.  Comparison of two skin protection regimes for the Prevention of Incontinence-associated Dermatitis in geriatric care (PID): a study protocol for an exploratory randomised controlled pragmatic trial.

Authors:  Monira El Genedy-Kalyoncu; Alexandra Fastner; Bettina Völzer; Kathrin Raeder; Konrad Neumann; Nils Axel Lahmann; Jan Kottner
Journal:  BMJ Open       Date:  2022-09-29       Impact factor: 3.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.